CEACAM5 and colorectal carcinoma: A phase I escalating-dose trial of (CAR)-T therapy targeting CEA-positive metastatic CRC, (CAR)-T cells at five dose levels (from 1 × 105 to 1 × 108 CAR/kg cells) has displayed safety and efficacy of treatment with tumor reduction observed in 7 out of 10 patients after (CAR)-T cell therapy [31].